Greece vs Trinidad and Tobago: Average non-HDL cholesterol levels
Greece
3.5
in 2018
Trinidad and Tobago
3.5
in 2018
Greece rank
52nd
Trinidad and Tobago rank
52nd
Average non-HDL cholesterol levels over time
- Greece
- Trinidad and Tobago
How they compare
Greece currently reports 3.5 against 3.5 in Trinidad and Tobago, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Greece ahead.
Greece ranks 52nd and Trinidad and Tobago ranks 52nd of 191 countries.
Greece has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Greece | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.18 | 3.5 | 0.68 | Greece |
| 1990s | 3.85 | 3.47 | 0.38 | Greece |
| 2000s | 3.61 | 3.42 | 0.19 | Greece |
| 2010s | 3.5 | 3.5 | 0 | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average non-hdl cholesterol levels, Greece or Trinidad and Tobago?
- Greece, at 3.5 against 3.5 in Trinidad and Tobago as of 2018.
- What is the difference in average non-hdl cholesterol levels between Greece and Trinidad and Tobago?
- 0, with Greece ahead.
- How many years of comparable data are there for Greece and Trinidad and Tobago?
- 39 years are reported by both, from 1980 to 2018.
- How do Greece and Trinidad and Tobago rank globally for average non-hdl cholesterol levels?
- Greece ranks 52nd and Trinidad and Tobago ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The estimated average level of non-high-density lipoprotein (non-HDL) cholesterol, commonly known as "bad cholesterol". Healthy levels are considered to be under 4mmol/L. Elevated levels of non-HDL cholesterol are a risk factor for chronic complications, including cardiovascular disease, and premature death.